A Study to Assess the Effect of Timing of Food Intake on the Pharmacokinetics of Abiraterone Following Single-Dose Administration of Abiraterone Acetate Tablets in Healthy Caucasian and Japanese Men

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

51 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-01-31

Study Completion Date

2012-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to evaluate the effect of timing of food intake on systemic abiraterone exposure observed in healthy adult Japanese and Caucasian men.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Study to Evaluate the Pharmacokinetics of Abiraterone in Healthy Chinese Male Participants

NCT01678573

Healthy

COMPLETED PHASE1

A Study to Determine the Effect of Food on the Pharmacokinetics of Abiraterone Acetate in Healthy Male Patients

NCT01798628

Healthy Volunteers

COMPLETED PHASE1

Effects of Metabolic Enzymes and Transporter Gene Polymorphisms on the Pharmacokinetics and Metabolism of Oral Abiraterone Acetate in Healthy Chinese Adults

NCT04735913

Abiraterone Acetate Gene Polymorphism Pharmacokinetic +2 more

UNKNOWN EARLY_PHASE1

A Study to Assess the Effect of Abiraterone Acetate in Male Participants With Mild or Moderate Hepatic Impairment Compared to Matched Control Participants With Normal Hepatic Function

NCT02001571

Prostate Cancer

COMPLETED PHASE1

A Pharmacokinetic Study of Abiraterone Acetate in Patients With Severe Hepatic Impairment Compared to Patients With Normal Hepatic Function

NCT01516047

Hepatic Impairment

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This is a randomized (individuals will be assigned by chance to study treatments), open-label (individuals will know the identity of study treatments), single dose, 4-way crossover study of abiraterone acetate in approximately 48 healthy adult Japanese and Caucasian men. For the crossover design, the treatment sequences are defined as follows: 1 - ADBC, 2 - BACD, 3 - CBDA, and 4 - DCAB; where Treatment A = abiraterone acetate administered in the fasted state, Treatment B = standardized meal administered 1 hour after abiraterone acetate dose, Treatment C = standardized meal administered 2 hours after abiraterone acetate dose, and Treatment D = standardized meal administered 2 hours before and 2 hours after abiraterone acetate dose. This study will consist of a screening period followed by four open-label treatment periods separated by a washout period of at least 14 days between dosing. Eligible participants will be randomly assigned on Day 1 to 1 of 4 treatment sequences that differ with regard to timing of food intake before and/or after dosing with a single dose of 1000 mg of abiraterone acetate. Serial pharmacokinetic (study of what the body does to a drug) samples will be collected during the open-label treatment phase as detailed in the protocol. Safety will be monitored throughout the study. End-of-study assessments will be performed on Day 4 of Period 4 or upon early withdrawal.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pharmacology

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment A

Group Type EXPERIMENTAL

Abiraterone: Treatment A

Intervention Type DRUG

1000 mg abiraterone acetate administered in the fasting state

Treatment B

Group Type EXPERIMENTAL

Abiraterone: Treatment B

Intervention Type DRUG

Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose

Treatment C

Group Type EXPERIMENTAL

Abiraterone: Treatment C

Intervention Type DRUG

Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose

Treatment D

Group Type EXPERIMENTAL

Abiraterone: Treatment D

Intervention Type DRUG

Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Abiraterone: Treatment A

1000 mg abiraterone acetate administered in the fasting state

Intervention Type DRUG

Abiraterone: Treatment B

Standardized meal administered 1 hour after the 1000 mg abiraterone acetate dose

Intervention Type DRUG

Abiraterone: Treatment C

Standardized meal administered 2 hours before the 1000 mg abiraterone acetate dose

Intervention Type DRUG

Abiraterone: Treatment D

Standardized meal administered 2 hours before and 2 hours after the 1000 mg abiraterone acetate dose

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy Caucasian and Japanese male individuals.
* Body mass index between 18 and 30 kg/m2.
* Body weight \>=50 kg.
* A normal 12-lead electrocardiogram.

Exclusion Criteria

* History of or current clinically significant medical illness that the investigator considers should exclude the participant or that could interfere with the interpretation of the study results.
* Presence of sexual dysfunction (abnormal libido, erectile dysfunction, etc.) or any medical condition that would affect sexual function.
* History of alcohol consumption of more than 4 drinks daily within 1 year prior to screening and unwillingness to abstain from alcohol-containing food or beverages from within 24 hours before Day-1 through study completion.
* History of, or a reason to believe a participant has a history of drug or alcohol abuse within the past 5 years.
* Positive test for human immunodeficiency virus 1 and 2 antibodies, hepatitis B surface antigen, or hepatitis C antibodies.
* History of smoking or use of nicotine-containing substances within the previous 2 months, as determined by medical history or participant's verbal report.

Minimum Eligible Age

25 Years

Maximum Eligible Age

35 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes